In HPV-related cancer prevention, molecular biological testing methods offer promising opportunities to detect cancer cells biomarkers. The biotechnology company oncgnostics GmbH regularly takes part in specialist conferences in order to exchange information about current research in this field.

At the Eurogin 2021 virtual congress, oncgnostics will be presenting the cervical cancer test GynTect and its application as well as the assay on Head-and-Neck cancer diagnostics, all based on the detection of epigenetic markers. The virtual exhibition takes place from Sunday, May 30 to Tuesday, June 1, 2021. Our managing directors Dr. Martina Schmitz and Dr. Alfred Hansel are available for questions and discussions at a digital booth.

Furthermore, the biotechnology company shows its expertise in two presentations. On Sunday, May 30th, 2021, Anna-Bawany Hums will talk about the research project on Head-and-Neck tumors in a session held between 3:45 pm to 5:15 pm: “A promising epigenetic biomarker for improved detection of Head-and-Neck cancer in non-invasive specimen”. The following Monday, May 31, 2021, Dr. Martina Schmitz presents a current study on the GynTect cervical cancer test in a session scheduled from 2:45 pm to 4:15 pm: “Performance of 6 methylation markers tested on self-collected urine samples – feasibility study”.

“We are pleased to be part of the Eurogin again and are looking forward to exchanging ideas with colleagues from science, industry and the media. The topic of cancer prevention needs constant innovations and cooperation so that those affected can quickly gain certainty about their disease status and thus can get access to treatment measures more quickly,” says Dr. Martina Schmitz.

Participation in virtual EEN and Bionnale brought interesting new contacts

“Off into the world” was the motto of the online event Enterprise Europe Network, at which oncgnostics presented itself as one of five companies at the beginning of May. The company has been part of the network for many years and values the thematic exchange, e.g. on topics such as the EU internal market or sustainable business models.

Oncgnostics also took part in the Bionnale. The networking event for the industries of life sciences and healthcare brings together companies and research institutions who are looking for joint development or research opportunities with innovative startups and investors. “In the virtual format of the event, we had the opportunity to directly make interesting new contacts, especially on research issues,” reports Dr. Peter Haug, who participated as Head of Business Development and Licensing for oncgnostics.